COVID-19 treatments: No magic bullet
11 June 2020
Life Sciences Research & Analysis COVID-19 treatments: No magic bullet 11 June 2020 Gustav Ando Janet Beal As communities, states, and countries...
Customer Logins
Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
Customer Logins
Janet Beal
Senior Research Analyst, Life Sciences, IHS Markit
Janet Beal specializes in the life sciences industry for the UK, Switzerland, Romania, Russia and CIS countries.
She has many years of experience covering the biotech/pharma R&D sector, as Biotech Editor and Research Support Manager at Pharmaprojects (Informa Citeline), and also worked for GlobalData and Thomson Derwent. She holds a BSc in Microbiology from the University of Aberdeen, and an MSc (by research) in Biochemistry and Applied Molecular Biology from the University of Manchester Institute of Science and Technology (UMIST). She has a reading knowledge of French, German, Hungarian and Romanian.
Related Content
-
-
UK bans parallel export of two COVID-19 treatment candidates to protect national supply
26 February 2020Life Sciences UK bans parallel export of two COVID-19 treatment candidates to protect national supply 26 February 2020 Janet Beal While the...
-
Zolgensma may be a potential game-changer for SMA
03 May 2019Life Sciences Zolgensma may be a potential game-changer for SMA 03 May 2019 Janet Beal Within the next month, the US Food and Drug Administration...
-
So, was this worth the wait?…the UK government finally responds to last year's Accelerated Access Review
03 November 2017Life Sciences So, was this worth the wait?…the UK government finally responds to last year's Accelerated Access Review 03 November 2017 Janet...
-
Time for a consultation on the impact of Brexit on the UK's access to medicines: Better late than never?
18 October 2017Life Sciences Time for a consultation on the impact of Brexit on the UK's access to medicines: Better late than never? 18 October 2017 Janet...
-
Can Affordable Medicines become a reality for Ukraine?
10 May 2017Life Sciences Can Affordable Medicines become a reality for Ukraine? 10 May 2017 Janet Beal A recent survey, "Cost(less) Medicine", commissioned...
-
Big dreams versus cost-saving schemes – will the UK dare to pursue its Accelerated Access ambitions in cash-strapped times?
18 November 2016Life Sciences Big dreams versus cost-saving schemes – will the UK dare to pursue its Accelerated Access ambitions in cash-strapped times? 18...
-
NICE's proposed Abbreviated Technology Appraisal scheme
14 June 2016Life Sciences Research & Analysis NICE's proposed Abbreviated Technology Appraisal scheme 14 June 2016 Janet Beal Faced with an ever-increasing...
View Similar Experts
Karim El Assir
Associate Director, Consulting, IHS Markit
Timothy Dall
Managing Director - Consulting, Life Sciences, Economics and Country Risk, IHS Markit
Gauri jauhar
Executive Director, Consulting